Pipeline

Pipeline


Product / Indication Pre Clinical Phase 1 Phase 2 Phase 3 NDA Review
Fostamatinib - ITP
Indication: Immune Thrombocytopenia
Target: SYK
  • 80%
Fostamatinib - IgAN
Indication: IgA Nephropathy
Target: SYK
  • 50%
Fostamatinib - AIHA
Indication: Autoimmune Hemolytic Anemia
Target: SYK
  • 50%
R428 (BGB324)
Indication: Cancer
Partner: BerGenBio
  • 42%
MDM2 Inhibitor (DS-3032)
Indication: Cancer
Partner: Daiichi Sankyo
  • 37%
JAK Inhibitors (ATI-50001)
Indication: Dermatology
Partner: Aclaris
  • 30%
TGF-beta Inhibitors
Indication: Cancer/Immunotherapy
Partner: Bristol-Myers Squibb
  • 18%
R256 (AZD0449)
Indication: Asthma
Partner: AstraZeneca
  • 15%
Investigator-sponsored Trials
Company-sponsored Trials